SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.
|Articles|August 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 8
- Volume 5
- Issue 8
Number of US HIV Infections Steady
BETHESDA, Md--The number of Americans infected with HIV is holding steady at about 650,000 to 900,000, according to CDC data. This may be because the number of new HIV infections each year is roughly equal to the annual number of AIDS-related deaths, the report said.
Advertisement
BETHESDA, Md--The number of Americans infected with HIV is holdingsteady at about 650,000 to 900,000, according to CDC data. Thismay be because the number of new HIV infections each year is roughlyequal to the annual number of AIDS-related deaths, the reportsaid.
Articles in this issue
about 30 years ago
Chemo Improves Pain Relief in Advanced Prostate Cancerabout 30 years ago
NCCR Urges Congress to Support Senate Bill for Cancer Researchabout 30 years ago
Researchers Propose New Treatment Guidelines for HIVabout 30 years ago
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Andersonabout 30 years ago
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samplesabout 30 years ago
New Thinking on HIV Progression Leads to New Strategiesabout 30 years ago
Hospitals Told Not to Capitate for 'Wrong' Reasonsabout 30 years ago
More Study Needed of Possible Carcinogenesis of Winter Gas Additiveabout 30 years ago
President Makes NCAB AppointmentsAdvertisement
Related to this article
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC
5